Selective COX-2 inhibitors for patients with arthritis: Are they safer than traditional nonsteroidal anti-inflammatory drugs?

Canadian Pharmaceutical Journal

Volumn 135, Issue 8, 2002, Pages 30-34

  MacAulay, Stacey ^a   Blackburn, David ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SUCRALFATE;

ACUTE KIDNEY FAILURE; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; REVIEW; SIDE EFFECT;

EID: 0036814024     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000;284:1247-55
2. FDA Medical Officer Review. Sept 20, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_O3_med.pdf. Accessed on May 2002
3. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
4. FDA Advisory Committee Briefing Document. Feb 8, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/O1/briefing/3677b2_03.med.doc. Accessed on May 2002.
5. Wright JM, Perry TL, Bassett KL et al. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001;286:2398-9
6. Wooltorton E. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ 2002;166:1692-3
7. Therapeutics Initiative. COX-2 inhibitors update: Do journal publications tell the full story? Therapeutics Letter 2001-2002; 43. Available at www.ti.ubc.ca. Accessed on July 2002
8. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002;89(suppl):3D-9D
9. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999;282:1921-8
10. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999;354:2106-11
11. Goldstein JL, Correa P, Zhao WW et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27
12. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterol 1999;117:776-83
13. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arth Rheum 2000;43:370-7
14. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterol 2001;120:594-606
15. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30
16. Gotzsche PC. Non-steroidal anti-inflammatory drugs. In: Barton S, ed. Clinical Evidence. 5th Ed. London: BMJ Publishing Group, 2001:800-7
17. Acevedo E, Castaneda O, Ugaz M et al. Tolerability profiles of rofecoxib (Vioxx) and arthrotec. Scand J Rheumatol 2001;30:19-24
18. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9
19. Watson DJ, Rhodes T, Cai B et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10
20. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111-5
21. Soloman DH, Glynn RJ, Levin R et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-1104
22. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: Clinical considerations. Am J Cardiol 2002;89(suppl):26D-32D
23. Harris RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002;89(suppl):10D-17D
24. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002;89(suppl):18D-25D
25. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107(6A):65S-71S
26. Brater DC, Harris C, Redefern JS et al. Renal effects of cox-2-selective inhibitors. Am J Nephrol 2001;21:1-15
27. Ahmad SR, Kortepeter C, Brinker A et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Safety 2002;25:537-44
28. Whelton A, Fort JG, Puma JA et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95
29. Zhao SZ, Reynolds MW, Lefkowith J et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the world health organization/Uppsala monitoring centre safety database. Clin Ther 2001;23:1478-91
30. FDA Arthritis Advisory Committee Meeting: Briefing Information. Feb 7, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm. Accessed on June 2002.
31. FDA Arthritis Advisory Committee Meeting: Briefing Information. Feb 8, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2.htm. Accessed on June 2002.
32. Moist L. The renal effects of COX-2 inhibitors. Can J CME 2001; Sept: 65-76.
33. Therapeutics Initiative. Serious adverse event analysis: Lipid-lowering therapy revisited. Therapeutics Letter 2001 (Aug-Oct); 42. Available at www.ti.ubc.ca. Accessed on September 2002.